2 at at Search Results


hmga2  (Proteintech)
95
Proteintech hmga2
SRM depletion enhances erdafitinib efficacy via <t>HMGA2.</t> A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).
Hmga2, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/HMGA2+Polyclonal+antibody/pmc12167931-79-31-33
Average 95 stars, based on 1 article reviews
hmga2 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
a 2 dwp at plate rotor  (Eppendorf AG)
96
Eppendorf AG a 2 dwp at plate rotor
SRM depletion enhances erdafitinib efficacy via <t>HMGA2.</t> A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).
A 2 Dwp At Plate Rotor, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/Rotor+A-2-DWP-AT/bio_rxiv__2021__05__11__443714-160-29-24
Average 96 stars, based on 1 article reviews
a 2 dwp at plate rotor - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
gabat inhibitor  (MedChemExpress)
90
MedChemExpress gabat inhibitor
SRM depletion enhances erdafitinib efficacy via <t>HMGA2.</t> A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).
Gabat Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/ABAT%2C+Human/pm36476877-264-12-18
Average 90 stars, based on 1 article reviews
gabat inhibitor - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ilf3  (OriGene)
90
OriGene ilf3
SRM depletion enhances erdafitinib efficacy via <t>HMGA2.</t> A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).
Ilf3, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/ILF3+(NM_012218)+Human+Tagged+ORF+Clone+Lentiviral+Particle/pm29556082-242-18-8
Average 90 stars, based on 1 article reviews
ilf3 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
pipette tips  (Accumax Lab Devices)
93
Accumax Lab Devices pipette tips
SRM depletion enhances erdafitinib efficacy via <t>HMGA2.</t> A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).
Pipette Tips, supplied by Accumax Lab Devices, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/Tips/pmc11372228-63-3-5
Average 93 stars, based on 1 article reviews
pipette tips - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
dss  (Chem Impex International)
95
Chem Impex International dss
SRM depletion enhances erdafitinib efficacy via <t>HMGA2.</t> A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).
Dss, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/Dextran+sulfate+sodium+salt/pm41955120-52-11-12
Average 95 stars, based on 1 article reviews
dss - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
human ilf3 cdna  (OriGene)
90
OriGene human ilf3 cdna
Figure 3. Screening the canine cohort for <t>ILF3</t> and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.
Human Ilf3 Cdna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/ILF3+(NM_012218)+Human+Tagged+ORF+Clone/pm29556082-242-0-8
Average 90 stars, based on 1 article reviews
human ilf3 cdna - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
at1001  (MedChemExpress)
92
MedChemExpress at1001
Figure 3. Screening the canine cohort for <t>ILF3</t> and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.
At1001, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/AT+1001/pm32561730-237-212-213
Average 92 stars, based on 1 article reviews
at1001 - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
mouse drinking water  (Chem Impex International)
95
Chem Impex International mouse drinking water
Figure 3. Screening the canine cohort for <t>ILF3</t> and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.
Mouse Drinking Water, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/Water/10__1038_slash_nm__3145__-621-33-39
Average 95 stars, based on 1 article reviews
mouse drinking water - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
acivicin  (MedChemExpress)
94
MedChemExpress acivicin
Figure 3. Screening the canine cohort for <t>ILF3</t> and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.
Acivicin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/Acivicin/bio_rxiv__2024__10__10__617667-137-7-8
Average 94 stars, based on 1 article reviews
acivicin - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
triphosgene  (Chem Impex International)
95
Chem Impex International triphosgene
Figure 3. Screening the canine cohort for <t>ILF3</t> and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.
Triphosgene, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/Triphosgene/us12569577-340-31-32
Average 95 stars, based on 1 article reviews
triphosgene - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
lysis buffer  (Chem Impex International)
95
Chem Impex International lysis buffer
Figure 3. Screening the canine cohort for <t>ILF3</t> and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.
Lysis Buffer, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/2+at+at/2-Amino-2-(hydroxymethyl)-1%2C3-propanediol+hydrochloride/pm42082831-402-18-41
Average 95 stars, based on 1 article reviews
lysis buffer - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


SRM depletion enhances erdafitinib efficacy via HMGA2. A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).

Journal: Cancer Research

Article Title: A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer

doi: 10.1158/0008-5472.CAN-24-3217

Figure Lengend Snippet: SRM depletion enhances erdafitinib efficacy via HMGA2. A, Intracellular polyamine metabolites levels measured by HPLC of WT and SRM KO MGH-U3 cells. CAD, cadaverine; SPM, spermine. B, Intracellular putrescine (PUT) and spermidine (SPD) levels measured by ELISA of MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours. C, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells. GAPDH was used as an internal control. D, Heatmap depicting the differentially expressed proteins between WT and SRM KO cells (left) or WT and SRM KO cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.005; right). Each group contained three independent replicates. Scale bar, log 2 -fold change. E, Venn diagram showing the lapping of the downregulated collection in group as depicted in D . Analysis pipeline was performed to identify proteins regulated by SRM KO: (i) 93 proteins were identified after overlapping; (ii) 20 proteins were selected with high abundance (WT count >6,000). Er, erdafitinib. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 or SW780 cells. GAPDH was used as an internal control. G, RIP assays in MGH-U3 cells using eIF5A and IgG antibody. The precipitate was subjected to Western blotting with the antibody against eIF5A. The eIF5A-enriched mRNAs relative to the IgG-enriched value was calculated by qRT-PCR. Scale bar, fold change. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. I, Cell Counting Kit-8 assay revealed the cell viability of WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2 treated with 100 nmol/L erdafitinib. J, Colony formation assay in the indicated MGH-U3 cells with erdafitinib treatment. K and L, In vivo growth curve ( K ) and representative of xenograft tumors ( L ) formed by subcutaneous injection of WT and SRM KO MGH-U3 cells and those transfected with HMGA2 into the right flanks of nude mice treated with erdafitinib (15 mg/kg; 5 × 10 6 cells per mouse; n = 6 for each group). M, IHC staining of Ki67 on WT and SRM KO MGH-U3 xenografts treated as in K . Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Student t test).

Article Snippet: Antibodies used included primary antibodies against GAPDH (60004-1-Ig, Proteintech, RRID: AB_2263076), SRM (19858-1-AP, Proteintech, RRID: AB_10665555), eIF5A (11309-1-AP, Proteintech, RRID: AB_2262001), eIF5A Hyp ( RGK08101 , AntibodySystem SAS, RRID: AB 3665852), HMGA2 (20795-1-AP, Proteintech, RRID: AB_2665377), EGFR (51071-2-AP, Proteintech, RRID: AB_10596476), AKT (10176-2-AP, Proteintech, RRID: AB_2224574), pAKT (80455-1-RR, Proteintech, RRID: AB_2918892), pEGFR(AP0992, ABclonal, RRID: AB_2863885), MYO1B (15012-1-AP, Proteintech, RRID: AB_10642004), LAMC2 (19698-1-AP, Proteintech, RRID: AB_10644139), IL1A (16765-1-AP, Proteintech, RRID: AB_10641044), ZNF185 (31477-1-AP, Proteintech, RRID: AB_3665885), ANXA8L1 (PA5-76232, Thermo Fisher Scientific, RRID: AB_2719959), ANXA3 (ab127924, Abcam, RRID: AB_11143246), SERPINC1 (A11249, ABclonal, RRID: AB_2861534), TGM2 (15100-1-AP, Proteintech, RRID: AB_2202885), RALA (13629-1-AP, Proteintech, RRID: AB_2269251), C1orf116 (14888-1-AP, Proteintech, RRID: AB_2228225), CAV1 (16447-1-AP, Proteintech, RRID: AB_10732595), KRT6A (10590-1-AP, Proteintech, RRID: AB_2134306), SBDS (17618-1-AP, Proteintech, RRID: AB_2184481), NSFL1C (15620-1-AP, Proteintech, RRID: AB_2878158), TXNDC5 (19834-1-AP, Proteintech, RRID: AB_10644285), TOMM34 (12196-1-AP, Proteintech, RRID: AB_2240906), EIF6 (10291-1-AP, Proteintech, RRID: AB_2096515), and SERPINB2 (16035-1-AP, Proteintech, RRID: AB_2186180).

Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Control, Quantitative RT-PCR, Transfection, Cell Counting, Colony Assay, In Vivo, Injection, Immunohistochemistry

SRM promotes the translation of HMGA2 by eIF5a hypusination. A, WT and SRM KO MGH-U3 cells were treated with 100 μmol/L spermidine in serum-free medium as indicated for 24 hours. GAPDH was used as internal control. B, MGH-U3 cells were treated with 10 μmol/L GC7 or PBS for 24 hours. eIF5A Hyp and HMGA2 levels were examined by Western blotting (left) and qRT-PCR (right). GAPDH was used as an internal control. C, MGH-U3 cells were treated with 10 μmol/L MCHA or DMSO for 96 hours. eIF5A Hyp and HMGA2 levels were examined by Western blotting (left) and qRT-PCR (right). GAPDH was used as an internal control. D, OPP pulldown assay for nascent protein synthesis. OPP is incorporated into newly translated proteins, and then the azide group on biotin is conjugated to an alkyne group on OPP by click reaction. Biotin-labeled proteins are pulled down by magnetic streptavidin beads and detected by Western blotting. E, The expression of newly synthesized HGMA2 protein of indicated MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours using the method shown in D . F, The mRNA from fractions taken during polyribosome profiling of WT and SRM KO MGH-U3 cells were isolated and quantified for HMGA2 . Actb, β-actin. G, Schematic of HMGA2-mCherry WT and mutant (MUT) constructs. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells transfected with indicated HMGA2-mCherry constructs from G . GAPDH was used as an internal control. Data are presented as the means ± SD from three independent experiments. ns, nonsignificant (Student t test). ns, nonsignificant.

Journal: Cancer Research

Article Title: A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer

doi: 10.1158/0008-5472.CAN-24-3217

Figure Lengend Snippet: SRM promotes the translation of HMGA2 by eIF5a hypusination. A, WT and SRM KO MGH-U3 cells were treated with 100 μmol/L spermidine in serum-free medium as indicated for 24 hours. GAPDH was used as internal control. B, MGH-U3 cells were treated with 10 μmol/L GC7 or PBS for 24 hours. eIF5A Hyp and HMGA2 levels were examined by Western blotting (left) and qRT-PCR (right). GAPDH was used as an internal control. C, MGH-U3 cells were treated with 10 μmol/L MCHA or DMSO for 96 hours. eIF5A Hyp and HMGA2 levels were examined by Western blotting (left) and qRT-PCR (right). GAPDH was used as an internal control. D, OPP pulldown assay for nascent protein synthesis. OPP is incorporated into newly translated proteins, and then the azide group on biotin is conjugated to an alkyne group on OPP by click reaction. Biotin-labeled proteins are pulled down by magnetic streptavidin beads and detected by Western blotting. E, The expression of newly synthesized HGMA2 protein of indicated MGH-U3 cells treated with 10 μmol/L MCHA or DMSO for 96 hours using the method shown in D . F, The mRNA from fractions taken during polyribosome profiling of WT and SRM KO MGH-U3 cells were isolated and quantified for HMGA2 . Actb, β-actin. G, Schematic of HMGA2-mCherry WT and mutant (MUT) constructs. H, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells transfected with indicated HMGA2-mCherry constructs from G . GAPDH was used as an internal control. Data are presented as the means ± SD from three independent experiments. ns, nonsignificant (Student t test). ns, nonsignificant.

Article Snippet: Antibodies used included primary antibodies against GAPDH (60004-1-Ig, Proteintech, RRID: AB_2263076), SRM (19858-1-AP, Proteintech, RRID: AB_10665555), eIF5A (11309-1-AP, Proteintech, RRID: AB_2262001), eIF5A Hyp ( RGK08101 , AntibodySystem SAS, RRID: AB 3665852), HMGA2 (20795-1-AP, Proteintech, RRID: AB_2665377), EGFR (51071-2-AP, Proteintech, RRID: AB_10596476), AKT (10176-2-AP, Proteintech, RRID: AB_2224574), pAKT (80455-1-RR, Proteintech, RRID: AB_2918892), pEGFR(AP0992, ABclonal, RRID: AB_2863885), MYO1B (15012-1-AP, Proteintech, RRID: AB_10642004), LAMC2 (19698-1-AP, Proteintech, RRID: AB_10644139), IL1A (16765-1-AP, Proteintech, RRID: AB_10641044), ZNF185 (31477-1-AP, Proteintech, RRID: AB_3665885), ANXA8L1 (PA5-76232, Thermo Fisher Scientific, RRID: AB_2719959), ANXA3 (ab127924, Abcam, RRID: AB_11143246), SERPINC1 (A11249, ABclonal, RRID: AB_2861534), TGM2 (15100-1-AP, Proteintech, RRID: AB_2202885), RALA (13629-1-AP, Proteintech, RRID: AB_2269251), C1orf116 (14888-1-AP, Proteintech, RRID: AB_2228225), CAV1 (16447-1-AP, Proteintech, RRID: AB_10732595), KRT6A (10590-1-AP, Proteintech, RRID: AB_2134306), SBDS (17618-1-AP, Proteintech, RRID: AB_2184481), NSFL1C (15620-1-AP, Proteintech, RRID: AB_2878158), TXNDC5 (19834-1-AP, Proteintech, RRID: AB_10644285), TOMM34 (12196-1-AP, Proteintech, RRID: AB_2240906), EIF6 (10291-1-AP, Proteintech, RRID: AB_2096515), and SERPINB2 (16035-1-AP, Proteintech, RRID: AB_2186180).

Techniques: Control, Western Blot, Quantitative RT-PCR, Labeling, Expressing, Synthesized, Isolation, Mutagenesis, Construct, Transfection

HMGA2 activates EGFR transcription. A, Heatmap depicted the differentially expressed genes between WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.05, absolute log 2 -fold change >1). Each group contained three independent replicates, respectively. Scale bar, log 2 -fold change. B, The expression of EGFR was detected by qRT-PCR in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib for 96 hours. C, ChIP analysis of HMGA2 enrichment at the indicated regions of the EGFR promoter in MGH-U3 cells. D, HMGA2-specific ChIP followed by RT-qPCR showed binding of HMGA2 to the EGFR promoter in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib or DMSO for 96 hours. The relative binding of HMGA2 to the EGFR promoter was calculated by first determining the HMGA2/input ratio for each group and then normalizing the KO groups to the WT group for comparison. E, Luciferase activity of the EGFR promoter in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib or DMSO for 96 hours. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib or DMSO for 96 hours. GAPDH was used as an internal control. G, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells treated with 10 or 100 nmol/L erdafitinib and DMSO for 96 hours. GAPDH was used as an internal control. H, The expression of HMGA2 was detected by qRT-PCR and Western blotting in MGH-U3 cells stably transfected with scramble, sh- HMGA2 #1, or sh- HMGA2 #2. GAPDH was used as an internal control. I, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001 (Student t test).

Journal: Cancer Research

Article Title: A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer

doi: 10.1158/0008-5472.CAN-24-3217

Figure Lengend Snippet: HMGA2 activates EGFR transcription. A, Heatmap depicted the differentially expressed genes between WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib for 96 hours ( P < 0.05, absolute log 2 -fold change >1). Each group contained three independent replicates, respectively. Scale bar, log 2 -fold change. B, The expression of EGFR was detected by qRT-PCR in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib for 96 hours. C, ChIP analysis of HMGA2 enrichment at the indicated regions of the EGFR promoter in MGH-U3 cells. D, HMGA2-specific ChIP followed by RT-qPCR showed binding of HMGA2 to the EGFR promoter in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib or DMSO for 96 hours. The relative binding of HMGA2 to the EGFR promoter was calculated by first determining the HMGA2/input ratio for each group and then normalizing the KO groups to the WT group for comparison. E, Luciferase activity of the EGFR promoter in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib or DMSO for 96 hours. F, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells treated with 100 nmol/L erdafitinib or DMSO for 96 hours. GAPDH was used as an internal control. G, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells treated with 10 or 100 nmol/L erdafitinib and DMSO for 96 hours. GAPDH was used as an internal control. H, The expression of HMGA2 was detected by qRT-PCR and Western blotting in MGH-U3 cells stably transfected with scramble, sh- HMGA2 #1, or sh- HMGA2 #2. GAPDH was used as an internal control. I, Western blotting with the indicated antibodies in WT and SRM KO MGH-U3 cells and those transfected with scramble or HMGA2. GAPDH was used as an internal control. Data are presented as the means ± SD from three independent experiments. **, P < 0.01; ***, P < 0.001 (Student t test).

Article Snippet: Antibodies used included primary antibodies against GAPDH (60004-1-Ig, Proteintech, RRID: AB_2263076), SRM (19858-1-AP, Proteintech, RRID: AB_10665555), eIF5A (11309-1-AP, Proteintech, RRID: AB_2262001), eIF5A Hyp ( RGK08101 , AntibodySystem SAS, RRID: AB 3665852), HMGA2 (20795-1-AP, Proteintech, RRID: AB_2665377), EGFR (51071-2-AP, Proteintech, RRID: AB_10596476), AKT (10176-2-AP, Proteintech, RRID: AB_2224574), pAKT (80455-1-RR, Proteintech, RRID: AB_2918892), pEGFR(AP0992, ABclonal, RRID: AB_2863885), MYO1B (15012-1-AP, Proteintech, RRID: AB_10642004), LAMC2 (19698-1-AP, Proteintech, RRID: AB_10644139), IL1A (16765-1-AP, Proteintech, RRID: AB_10641044), ZNF185 (31477-1-AP, Proteintech, RRID: AB_3665885), ANXA8L1 (PA5-76232, Thermo Fisher Scientific, RRID: AB_2719959), ANXA3 (ab127924, Abcam, RRID: AB_11143246), SERPINC1 (A11249, ABclonal, RRID: AB_2861534), TGM2 (15100-1-AP, Proteintech, RRID: AB_2202885), RALA (13629-1-AP, Proteintech, RRID: AB_2269251), C1orf116 (14888-1-AP, Proteintech, RRID: AB_2228225), CAV1 (16447-1-AP, Proteintech, RRID: AB_10732595), KRT6A (10590-1-AP, Proteintech, RRID: AB_2134306), SBDS (17618-1-AP, Proteintech, RRID: AB_2184481), NSFL1C (15620-1-AP, Proteintech, RRID: AB_2878158), TXNDC5 (19834-1-AP, Proteintech, RRID: AB_10644285), TOMM34 (12196-1-AP, Proteintech, RRID: AB_2240906), EIF6 (10291-1-AP, Proteintech, RRID: AB_2096515), and SERPINB2 (16035-1-AP, Proteintech, RRID: AB_2186180).

Techniques: Expressing, Quantitative RT-PCR, Binding Assay, Comparison, Luciferase, Activity Assay, Western Blot, Control, Stable Transfection, Transfection

Figure 3. Screening the canine cohort for ILF3 and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.

Journal: Scientific reports

Article Title: ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease.

doi: 10.1038/s41598-018-23034-w

Figure Lengend Snippet: Figure 3. Screening the canine cohort for ILF3 and RBMX autoantibodies. A radio-ligand binding assay was used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.

Article Snippet: Human ILF3 cDNA in a pCMV6-Entry vector (RC214999, Origene) was used for in vitro transcription and translation of ILF3.

Techniques: Radio Ligand Binding Assay, Negative Control, Positive Control

Figure 5. Sera from ILF2- and ILF3-positive patients and commercial ILF2 and ILF3 antibodies display a speckled ANA pattern. Indirect immunofluorescence microscopy images of HEp-2 cells incubated with sera from an ILF2- and ILF3-positive IMRD patient (a), a commercial polyclonal ILF2 antibody (b); and a commercial polyclonal ILF3 antibody (c). (a) In the nucleoplasm, fine tiny speckles can be observed and mitotic cells have unstained chromatin mass (⇨). The nucleoli are not stained (→). (b,c) In the nucleoplasm, fine tiny speckles can be observed and mitotic cells have unstained chromatin mass (⇨). Nucleoli are stained in many of the cells (→) but not all.

Journal: Scientific reports

Article Title: ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease.

doi: 10.1038/s41598-018-23034-w

Figure Lengend Snippet: Figure 5. Sera from ILF2- and ILF3-positive patients and commercial ILF2 and ILF3 antibodies display a speckled ANA pattern. Indirect immunofluorescence microscopy images of HEp-2 cells incubated with sera from an ILF2- and ILF3-positive IMRD patient (a), a commercial polyclonal ILF2 antibody (b); and a commercial polyclonal ILF3 antibody (c). (a) In the nucleoplasm, fine tiny speckles can be observed and mitotic cells have unstained chromatin mass (⇨). The nucleoli are not stained (→). (b,c) In the nucleoplasm, fine tiny speckles can be observed and mitotic cells have unstained chromatin mass (⇨). Nucleoli are stained in many of the cells (→) but not all.

Article Snippet: Human ILF3 cDNA in a pCMV6-Entry vector (RC214999, Origene) was used for in vitro transcription and translation of ILF3.

Techniques: Immunofluorescence, Microscopy, Incubation, Staining